Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent

Janssen Alleges Compound And UC Patents Infringed By ABP 654 Biosimilar

 Amgen logo sign hanging on the office building in Rotkreuz, Switzerland
Amgen targets ustekinumab among the next wave • Source: Alamy/Marlon Trottmann

More from Biosimilars

More from Products